Nuvalent describes new ROS and ALK tyrosine kinase receptor inhibitors

April 22, 2025

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 24, 2025.

Illustration of group of people with chromosomes floating above

A fresh look at 1000 Genomes is more detailed, and more panoramic

BioWorld

The human genome has yielded another round of secrets with the publication of two back-to-back papers in Nature on July 23, 2025. Both studies re-sequenced...

Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

BioWorld

The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...

Abivax’s obefazimod wows investors; stock climbs 500%+

BioWorld

Abivax SA is positioning to change the treatment landscape in ulcerative colitis after delivering positive results and a favorable safety profile in two phase III...